YK-029A

Cat. No.:	HY-155537
CAS No.:	2064269-82-3
Molecular Formula:	$C_{27}H_{32}N_8O_2$
Molecular Weight:	500.6
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (199.76 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9976 mL	9.9880 mL	19.9760 mL
	5 mM	0.3995 mL	1.9976 mL	3.9952 mL
	10 mM	0.1998 mL	0.9988 mL	1.9976 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (4.99 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (4.99 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

YK-029A is an orally active inhibitor of mutant EGFR targeting to both the T790M mutations ($EGFR^{T790M}$) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity and results tumor regression in EGFRex20ins-driven PDX models[1].

IC_{50} & Target

$EGFR^{T790M}$, EGFRex20ins[1]

REFERENCES

[1]. Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA